Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 V116 vs comparators in children and adolescents at increased risk of pneumococcal disease
2023-506236-32-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants with solicited injection-site adverse events, Percentage of participants with solicited systemic adverse events and 2 more. Started Mar 2024; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2023-506236-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506236-32-00.